nodes	percent_of_prediction	percent_of_DWPC	metapath
Dolasetron—CYP2C9—Formoterol—chronic obstructive pulmonary disease	0.0883	0.123	CbGbCtD
Dolasetron—CYP2C9—Arformoterol—chronic obstructive pulmonary disease	0.0883	0.123	CbGbCtD
Dolasetron—CYP2D6—Formoterol—chronic obstructive pulmonary disease	0.0807	0.113	CbGbCtD
Dolasetron—CYP2D6—Arformoterol—chronic obstructive pulmonary disease	0.0807	0.113	CbGbCtD
Dolasetron—CYP2D6—Tiotropium—chronic obstructive pulmonary disease	0.072	0.1	CbGbCtD
Dolasetron—CYP3A4—Salbutamol—chronic obstructive pulmonary disease	0.0677	0.0944	CbGbCtD
Dolasetron—CYP2C9—Montelukast—chronic obstructive pulmonary disease	0.0669	0.0933	CbGbCtD
Dolasetron—CYP3A4—Tiotropium—chronic obstructive pulmonary disease	0.0458	0.0638	CbGbCtD
Dolasetron—CYP3A4—Aminophylline—chronic obstructive pulmonary disease	0.0437	0.0608	CbGbCtD
Dolasetron—CYP3A4—Montelukast—chronic obstructive pulmonary disease	0.0389	0.0542	CbGbCtD
Dolasetron—CYP3A4—Prednisolone—chronic obstructive pulmonary disease	0.0228	0.0318	CbGbCtD
Dolasetron—CYP3A4—Prednisone—chronic obstructive pulmonary disease	0.0216	0.0301	CbGbCtD
Dolasetron—CYP3A4—Lidocaine metabolism—CYP1A2—chronic obstructive pulmonary disease	0.0022	0.0599	CbGpPWpGaD
Dolasetron—CYP3A4—Aflatoxin B1 metabolism—EPHX1—chronic obstructive pulmonary disease	0.00194	0.0529	CbGpPWpGaD
Dolasetron—HTR3A—Ion channel transport—ATP2C2—chronic obstructive pulmonary disease	0.00188	0.0513	CbGpPWpGaD
Dolasetron—HTR3A—Ion channel transport—TRPV4—chronic obstructive pulmonary disease	0.00168	0.0457	CbGpPWpGaD
Dolasetron—CYP3A4—Benzo(a)pyrene metabolism—EPHX1—chronic obstructive pulmonary disease	0.00159	0.0433	CbGpPWpGaD
Dolasetron—Atropine—CYP1A2—chronic obstructive pulmonary disease	0.00156	1	CrCbGaD
Dolasetron—CYP2C9—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A2—chronic obstructive pulmonary disease	0.0011	0.0299	CbGpPWpGaD
Dolasetron—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—chronic obstructive pulmonary disease	0.00102	0.0278	CbGpPWpGaD
Dolasetron—CYP2C9—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A2—chronic obstructive pulmonary disease	0.001	0.0273	CbGpPWpGaD
Dolasetron—CYP3A4—Aflatoxin B1 metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000807	0.022	CbGpPWpGaD
Dolasetron—CYP2C9—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1A1—chronic obstructive pulmonary disease	0.000799	0.0218	CbGpPWpGaD
Dolasetron—CYP2C9—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1A1—chronic obstructive pulmonary disease	0.000727	0.0198	CbGpPWpGaD
Dolasetron—HTR3A—Transmembrane transport of small molecules—ATP2C2—chronic obstructive pulmonary disease	0.000655	0.0178	CbGpPWpGaD
Dolasetron—CYP2D6—Fatty Acid Omega Oxidation—CYP1A2—chronic obstructive pulmonary disease	0.000637	0.0173	CbGpPWpGaD
Dolasetron—CYP3A4—Aflatoxin B1 metabolism—GSTM1—chronic obstructive pulmonary disease	0.000618	0.0168	CbGpPWpGaD
Dolasetron—HTR3A—Transmembrane transport of small molecules—TRPV4—chronic obstructive pulmonary disease	0.000584	0.0159	CbGpPWpGaD
Dolasetron—HTR3A—SIDS Susceptibility Pathways—IL13—chronic obstructive pulmonary disease	0.000567	0.0154	CbGpPWpGaD
Dolasetron—CYP2D6—Xenobiotics—CYP1A2—chronic obstructive pulmonary disease	0.000533	0.0145	CbGpPWpGaD
Dolasetron—CYP2C9—Xenobiotics—CYP1A2—chronic obstructive pulmonary disease	0.000528	0.0144	CbGpPWpGaD
Dolasetron—CYP2D6—Tamoxifen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000512	0.014	CbGpPWpGaD
Dolasetron—HTR3A—SIDS Susceptibility Pathways—SLC6A4—chronic obstructive pulmonary disease	0.000511	0.0139	CbGpPWpGaD
Dolasetron—CYP2C9—Tamoxifen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000508	0.0138	CbGpPWpGaD
Dolasetron—Agitation—Montelukast—chronic obstructive pulmonary disease	0.000503	0.00206	CcSEcCtD
Dolasetron—Angioedema—Montelukast—chronic obstructive pulmonary disease	0.0005	0.00205	CcSEcCtD
Dolasetron—Dyspepsia—Tiotropium—chronic obstructive pulmonary disease	0.000498	0.00204	CcSEcCtD
Dolasetron—Tremor—Salbutamol—chronic obstructive pulmonary disease	0.000495	0.00202	CcSEcCtD
Dolasetron—Palpitations—Arformoterol—chronic obstructive pulmonary disease	0.000494	0.00202	CcSEcCtD
Dolasetron—Palpitations—Formoterol—chronic obstructive pulmonary disease	0.000494	0.00202	CcSEcCtD
Dolasetron—Gastrointestinal pain—Aminophylline—chronic obstructive pulmonary disease	0.00049	0.00201	CcSEcCtD
Dolasetron—Ill-defined disorder—Salbutamol—chronic obstructive pulmonary disease	0.00049	0.002	CcSEcCtD
Dolasetron—Cough—Arformoterol—chronic obstructive pulmonary disease	0.000488	0.002	CcSEcCtD
Dolasetron—Cough—Formoterol—chronic obstructive pulmonary disease	0.000488	0.002	CcSEcCtD
Dolasetron—Agitation—Salbutamol—chronic obstructive pulmonary disease	0.000485	0.00199	CcSEcCtD
Dolasetron—Palpitations—Montelukast—chronic obstructive pulmonary disease	0.000484	0.00198	CcSEcCtD
Dolasetron—Constipation—Tiotropium—chronic obstructive pulmonary disease	0.000483	0.00198	CcSEcCtD
Dolasetron—Hypertension—Arformoterol—chronic obstructive pulmonary disease	0.000483	0.00198	CcSEcCtD
Dolasetron—Hypertension—Formoterol—chronic obstructive pulmonary disease	0.000483	0.00198	CcSEcCtD
Dolasetron—Angioedema—Salbutamol—chronic obstructive pulmonary disease	0.000482	0.00197	CcSEcCtD
Dolasetron—CYP3A4—Benzo(a)pyrene metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000479	0.0131	CbGpPWpGaD
Dolasetron—Cardiac arrest—Prednisolone—chronic obstructive pulmonary disease	0.000478	0.00196	CcSEcCtD
Dolasetron—Cough—Montelukast—chronic obstructive pulmonary disease	0.000478	0.00196	CcSEcCtD
Dolasetron—Urticaria—Aminophylline—chronic obstructive pulmonary disease	0.000476	0.00195	CcSEcCtD
Dolasetron—Malaise—Salbutamol—chronic obstructive pulmonary disease	0.000476	0.00195	CcSEcCtD
Dolasetron—Myalgia—Formoterol—chronic obstructive pulmonary disease	0.000476	0.00195	CcSEcCtD
Dolasetron—Arthralgia—Arformoterol—chronic obstructive pulmonary disease	0.000476	0.00195	CcSEcCtD
Dolasetron—Chest pain—Formoterol—chronic obstructive pulmonary disease	0.000476	0.00195	CcSEcCtD
Dolasetron—Arthralgia—Formoterol—chronic obstructive pulmonary disease	0.000476	0.00195	CcSEcCtD
Dolasetron—Chest pain—Arformoterol—chronic obstructive pulmonary disease	0.000476	0.00195	CcSEcCtD
Dolasetron—Myalgia—Arformoterol—chronic obstructive pulmonary disease	0.000476	0.00195	CcSEcCtD
Dolasetron—Convulsion—Montelukast—chronic obstructive pulmonary disease	0.000474	0.00194	CcSEcCtD
Dolasetron—Anxiety—Arformoterol—chronic obstructive pulmonary disease	0.000474	0.00194	CcSEcCtD
Dolasetron—Anxiety—Formoterol—chronic obstructive pulmonary disease	0.000474	0.00194	CcSEcCtD
Dolasetron—Vertigo—Salbutamol—chronic obstructive pulmonary disease	0.000474	0.00194	CcSEcCtD
Dolasetron—Body temperature increased—Aminophylline—chronic obstructive pulmonary disease	0.000474	0.00194	CcSEcCtD
Dolasetron—Abdominal pain—Aminophylline—chronic obstructive pulmonary disease	0.000474	0.00194	CcSEcCtD
Dolasetron—Syncope—Salbutamol—chronic obstructive pulmonary disease	0.000473	0.00194	CcSEcCtD
Dolasetron—Discomfort—Formoterol—chronic obstructive pulmonary disease	0.00047	0.00192	CcSEcCtD
Dolasetron—Discomfort—Arformoterol—chronic obstructive pulmonary disease	0.00047	0.00192	CcSEcCtD
Dolasetron—Palpitations—Salbutamol—chronic obstructive pulmonary disease	0.000466	0.00191	CcSEcCtD
Dolasetron—Arthralgia—Montelukast—chronic obstructive pulmonary disease	0.000466	0.00191	CcSEcCtD
Dolasetron—Myalgia—Montelukast—chronic obstructive pulmonary disease	0.000466	0.00191	CcSEcCtD
Dolasetron—Dry mouth—Arformoterol—chronic obstructive pulmonary disease	0.000465	0.00191	CcSEcCtD
Dolasetron—Dry mouth—Formoterol—chronic obstructive pulmonary disease	0.000465	0.00191	CcSEcCtD
Dolasetron—Anxiety—Montelukast—chronic obstructive pulmonary disease	0.000465	0.0019	CcSEcCtD
Dolasetron—Loss of consciousness—Salbutamol—chronic obstructive pulmonary disease	0.000464	0.0019	CcSEcCtD
Dolasetron—CYP2D6—Fatty Acid Omega Oxidation—CYP1A1—chronic obstructive pulmonary disease	0.000463	0.0126	CbGpPWpGaD
Dolasetron—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	0.000462	0.00189	CcSEcCtD
Dolasetron—Cough—Salbutamol—chronic obstructive pulmonary disease	0.000461	0.00189	CcSEcCtD
Dolasetron—Oedema—Arformoterol—chronic obstructive pulmonary disease	0.000456	0.00187	CcSEcCtD
Dolasetron—Anaphylactic shock—Arformoterol—chronic obstructive pulmonary disease	0.000456	0.00187	CcSEcCtD
Dolasetron—Anaphylactic shock—Formoterol—chronic obstructive pulmonary disease	0.000456	0.00187	CcSEcCtD
Dolasetron—Oedema—Formoterol—chronic obstructive pulmonary disease	0.000456	0.00187	CcSEcCtD
Dolasetron—Hypertension—Salbutamol—chronic obstructive pulmonary disease	0.000456	0.00187	CcSEcCtD
Dolasetron—Chest pain—Salbutamol—chronic obstructive pulmonary disease	0.000449	0.00184	CcSEcCtD
Dolasetron—Arthralgia—Salbutamol—chronic obstructive pulmonary disease	0.000449	0.00184	CcSEcCtD
Dolasetron—Myalgia—Salbutamol—chronic obstructive pulmonary disease	0.000449	0.00184	CcSEcCtD
Dolasetron—Urticaria—Tiotropium—chronic obstructive pulmonary disease	0.000449	0.00184	CcSEcCtD
Dolasetron—Anxiety—Salbutamol—chronic obstructive pulmonary disease	0.000448	0.00183	CcSEcCtD
Dolasetron—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.000447	0.00183	CcSEcCtD
Dolasetron—Anaphylactic shock—Montelukast—chronic obstructive pulmonary disease	0.000447	0.00183	CcSEcCtD
Dolasetron—Oedema—Montelukast—chronic obstructive pulmonary disease	0.000447	0.00183	CcSEcCtD
Dolasetron—Tachycardia—Arformoterol—chronic obstructive pulmonary disease	0.000445	0.00182	CcSEcCtD
Dolasetron—Tachycardia—Formoterol—chronic obstructive pulmonary disease	0.000445	0.00182	CcSEcCtD
Dolasetron—Discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000444	0.00182	CcSEcCtD
Dolasetron—Hypersensitivity—Aminophylline—chronic obstructive pulmonary disease	0.000442	0.00181	CcSEcCtD
Dolasetron—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.00044	0.0018	CcSEcCtD
Dolasetron—Thrombocytopenia—Montelukast—chronic obstructive pulmonary disease	0.000438	0.00179	CcSEcCtD
Dolasetron—Abdominal distension—Prednisolone—chronic obstructive pulmonary disease	0.000437	0.00179	CcSEcCtD
Dolasetron—Sepsis—Prednisone—chronic obstructive pulmonary disease	0.000437	0.00179	CcSEcCtD
Dolasetron—Anaphylactic shock—Salbutamol—chronic obstructive pulmonary disease	0.000431	0.00176	CcSEcCtD
Dolasetron—Oedema—Salbutamol—chronic obstructive pulmonary disease	0.000431	0.00176	CcSEcCtD
Dolasetron—Hypotension—Formoterol—chronic obstructive pulmonary disease	0.000426	0.00175	CcSEcCtD
Dolasetron—Hypotension—Arformoterol—chronic obstructive pulmonary disease	0.000426	0.00175	CcSEcCtD
Dolasetron—Pancreatitis—Prednisolone—chronic obstructive pulmonary disease	0.000426	0.00174	CcSEcCtD
Dolasetron—Pruritus—Aminophylline—chronic obstructive pulmonary disease	0.000424	0.00174	CcSEcCtD
Dolasetron—Shock—Salbutamol—chronic obstructive pulmonary disease	0.000424	0.00174	CcSEcCtD
Dolasetron—Sweating increased—Prednisolone—chronic obstructive pulmonary disease	0.000423	0.00173	CcSEcCtD
Dolasetron—Thrombophlebitis—Prednisone—chronic obstructive pulmonary disease	0.000422	0.00173	CcSEcCtD
Dolasetron—Tachycardia—Salbutamol—chronic obstructive pulmonary disease	0.00042	0.00172	CcSEcCtD
Dolasetron—Hypersensitivity—Tiotropium—chronic obstructive pulmonary disease	0.000417	0.00171	CcSEcCtD
Dolasetron—Hyperhidrosis—Salbutamol—chronic obstructive pulmonary disease	0.000416	0.0017	CcSEcCtD
Dolasetron—CYP3A4—Fatty Acid Omega Oxidation—CYP1A2—chronic obstructive pulmonary disease	0.000416	0.0113	CbGpPWpGaD
Dolasetron—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	0.000416	0.0017	CcSEcCtD
Dolasetron—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000416	0.0017	CcSEcCtD
Dolasetron—Anorexia—Salbutamol—chronic obstructive pulmonary disease	0.000411	0.00168	CcSEcCtD
Dolasetron—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.00041	0.00168	CcSEcCtD
Dolasetron—Vascular purpura—Prednisone—chronic obstructive pulmonary disease	0.000408	0.00167	CcSEcCtD
Dolasetron—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	0.000407	0.00167	CcSEcCtD
Dolasetron—Dyspnoea—Formoterol—chronic obstructive pulmonary disease	0.000407	0.00167	CcSEcCtD
Dolasetron—Dyspnoea—Arformoterol—chronic obstructive pulmonary disease	0.000407	0.00167	CcSEcCtD
Dolasetron—Somnolence—Formoterol—chronic obstructive pulmonary disease	0.000406	0.00166	CcSEcCtD
Dolasetron—Somnolence—Arformoterol—chronic obstructive pulmonary disease	0.000406	0.00166	CcSEcCtD
Dolasetron—Hypotension—Salbutamol—chronic obstructive pulmonary disease	0.000403	0.00165	CcSEcCtD
Dolasetron—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	0.000402	0.00164	CcSEcCtD
Dolasetron—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	0.000402	0.00164	CcSEcCtD
Dolasetron—Paraesthesia—Montelukast—chronic obstructive pulmonary disease	0.000401	0.00164	CcSEcCtD
Dolasetron—Pruritus—Tiotropium—chronic obstructive pulmonary disease	0.0004	0.00164	CcSEcCtD
Dolasetron—Somnolence—Montelukast—chronic obstructive pulmonary disease	0.000397	0.00163	CcSEcCtD
Dolasetron—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000396	0.00162	CcSEcCtD
Dolasetron—CYP2D6—Melatonin metabolism and effects—CYP1A2—chronic obstructive pulmonary disease	0.000396	0.0108	CbGpPWpGaD
Dolasetron—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	0.000393	0.00161	CcSEcCtD
Dolasetron—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.000393	0.00161	CcSEcCtD
Dolasetron—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.000393	0.00161	CcSEcCtD
Dolasetron—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000393	0.00161	CcSEcCtD
Dolasetron—Constipation—Formoterol—chronic obstructive pulmonary disease	0.00039	0.0016	CcSEcCtD
Dolasetron—Constipation—Arformoterol—chronic obstructive pulmonary disease	0.00039	0.0016	CcSEcCtD
Dolasetron—Pain—Formoterol—chronic obstructive pulmonary disease	0.00039	0.0016	CcSEcCtD
Dolasetron—Pain—Arformoterol—chronic obstructive pulmonary disease	0.00039	0.0016	CcSEcCtD
Dolasetron—Increased appetite—Prednisone—chronic obstructive pulmonary disease	0.000389	0.00159	CcSEcCtD
Dolasetron—CYP2D6—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.000387	0.0105	CbGpPWpGaD
Dolasetron—Paraesthesia—Salbutamol—chronic obstructive pulmonary disease	0.000387	0.00158	CcSEcCtD
Dolasetron—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.000385	0.00158	CcSEcCtD
Dolasetron—Dyspnoea—Salbutamol—chronic obstructive pulmonary disease	0.000384	0.00157	CcSEcCtD
Dolasetron—CYP2C9—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.000384	0.0105	CbGpPWpGaD
Dolasetron—Somnolence—Salbutamol—chronic obstructive pulmonary disease	0.000383	0.00157	CcSEcCtD
Dolasetron—Pain—Montelukast—chronic obstructive pulmonary disease	0.000382	0.00156	CcSEcCtD
Dolasetron—Acute coronary syndrome—Prednisolone—chronic obstructive pulmonary disease	0.000382	0.00156	CcSEcCtD
Dolasetron—Myocardial infarction—Prednisolone—chronic obstructive pulmonary disease	0.00038	0.00155	CcSEcCtD
Dolasetron—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	0.000379	0.00155	CcSEcCtD
Dolasetron—Purpura—Prednisone—chronic obstructive pulmonary disease	0.000379	0.00155	CcSEcCtD
Dolasetron—CYP3A4—Estrogen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000379	0.0103	CbGpPWpGaD
Dolasetron—Rash—Aminophylline—chronic obstructive pulmonary disease	0.000378	0.00155	CcSEcCtD
Dolasetron—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.000378	0.00155	CcSEcCtD
Dolasetron—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	0.000376	0.00154	CcSEcCtD
Dolasetron—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	0.000376	0.00154	CcSEcCtD
Dolasetron—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000376	0.00154	CcSEcCtD
Dolasetron—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	0.000375	0.00153	CcSEcCtD
Dolasetron—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000374	0.00153	CcSEcCtD
Dolasetron—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.000373	0.00153	CcSEcCtD
Dolasetron—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.000373	0.00153	CcSEcCtD
Dolasetron—CYP2D6—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000372	0.0101	CbGpPWpGaD
Dolasetron—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.000371	0.00152	CcSEcCtD
Dolasetron—CYP2C9—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000369	0.0101	CbGpPWpGaD
Dolasetron—Constipation—Salbutamol—chronic obstructive pulmonary disease	0.000368	0.00151	CcSEcCtD
Dolasetron—Pain—Salbutamol—chronic obstructive pulmonary disease	0.000368	0.00151	CcSEcCtD
Dolasetron—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.000365	0.0015	CcSEcCtD
Dolasetron—CYP3A4—Aflatoxin activation and detoxification—CYP1A2—chronic obstructive pulmonary disease	0.000363	0.00989	CbGpPWpGaD
Dolasetron—Urticaria—Arformoterol—chronic obstructive pulmonary disease	0.000362	0.00148	CcSEcCtD
Dolasetron—Urticaria—Formoterol—chronic obstructive pulmonary disease	0.000362	0.00148	CcSEcCtD
Dolasetron—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	0.000361	0.00148	CcSEcCtD
Dolasetron—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.000361	0.00148	CcSEcCtD
Dolasetron—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.000361	0.00148	CcSEcCtD
Dolasetron—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	0.000361	0.00148	CcSEcCtD
Dolasetron—Rash—Tiotropium—chronic obstructive pulmonary disease	0.000356	0.00146	CcSEcCtD
Dolasetron—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.000356	0.00146	CcSEcCtD
Dolasetron—Urticaria—Montelukast—chronic obstructive pulmonary disease	0.000355	0.00145	CcSEcCtD
Dolasetron—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	0.000355	0.00145	CcSEcCtD
Dolasetron—HTR3A—SIDS Susceptibility Pathways—IL10—chronic obstructive pulmonary disease	0.000354	0.00966	CbGpPWpGaD
Dolasetron—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000354	0.00145	CcSEcCtD
Dolasetron—Bradycardia—Prednisolone—chronic obstructive pulmonary disease	0.000354	0.00145	CcSEcCtD
Dolasetron—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	0.000353	0.00145	CcSEcCtD
Dolasetron—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.000353	0.00145	CcSEcCtD
Dolasetron—Face oedema—Prednisone—chronic obstructive pulmonary disease	0.000353	0.00144	CcSEcCtD
Dolasetron—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.000352	0.00144	CcSEcCtD
Dolasetron—CYP3A4—Xenobiotics—CYP1A2—chronic obstructive pulmonary disease	0.000348	0.00949	CbGpPWpGaD
Dolasetron—Cardiac arrest—Prednisone—chronic obstructive pulmonary disease	0.000347	0.00142	CcSEcCtD
Dolasetron—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP1A2—chronic obstructive pulmonary disease	0.000345	0.00941	CbGpPWpGaD
Dolasetron—Urticaria—Salbutamol—chronic obstructive pulmonary disease	0.000342	0.0014	CcSEcCtD
Dolasetron—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	0.000341	0.00139	CcSEcCtD
Dolasetron—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.000341	0.00139	CcSEcCtD
Dolasetron—Hypersensitivity—Arformoterol—chronic obstructive pulmonary disease	0.000336	0.00138	CcSEcCtD
Dolasetron—Hypersensitivity—Formoterol—chronic obstructive pulmonary disease	0.000336	0.00138	CcSEcCtD
Dolasetron—Visual impairment—Prednisolone—chronic obstructive pulmonary disease	0.000335	0.00137	CcSEcCtD
Dolasetron—CYP3A4—Tamoxifen metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000335	0.00913	CbGpPWpGaD
Dolasetron—Hypersensitivity—Montelukast—chronic obstructive pulmonary disease	0.000329	0.00135	CcSEcCtD
Dolasetron—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000327	0.00134	CcSEcCtD
Dolasetron—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000327	0.00134	CcSEcCtD
Dolasetron—Pruritus—Formoterol—chronic obstructive pulmonary disease	0.000323	0.00132	CcSEcCtD
Dolasetron—Pruritus—Arformoterol—chronic obstructive pulmonary disease	0.000323	0.00132	CcSEcCtD
Dolasetron—Alanine aminotransferase increased—Prednisone—chronic obstructive pulmonary disease	0.000322	0.00132	CcSEcCtD
Dolasetron—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000321	0.00131	CcSEcCtD
Dolasetron—Abdominal distension—Prednisone—chronic obstructive pulmonary disease	0.000318	0.0013	CcSEcCtD
Dolasetron—Hypersensitivity—Salbutamol—chronic obstructive pulmonary disease	0.000317	0.0013	CcSEcCtD
Dolasetron—Pruritus—Montelukast—chronic obstructive pulmonary disease	0.000316	0.00129	CcSEcCtD
Dolasetron—HTR3A—SIDS Susceptibility Pathways—HTR2A—chronic obstructive pulmonary disease	0.000314	0.00855	CbGpPWpGaD
Dolasetron—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000312	0.00128	CcSEcCtD
Dolasetron—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000312	0.00128	CcSEcCtD
Dolasetron—Arrhythmia—Prednisolone—chronic obstructive pulmonary disease	0.000311	0.00127	CcSEcCtD
Dolasetron—Pancreatitis—Prednisone—chronic obstructive pulmonary disease	0.00031	0.00127	CcSEcCtD
Dolasetron—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000309	0.00127	CcSEcCtD
Dolasetron—Sweating increased—Prednisone—chronic obstructive pulmonary disease	0.000308	0.00126	CcSEcCtD
Dolasetron—CYP2D6—Melatonin metabolism and effects—EDN1—chronic obstructive pulmonary disease	0.000307	0.00836	CbGpPWpGaD
Dolasetron—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.000306	0.00125	CcSEcCtD
Dolasetron—Pruritus—Salbutamol—chronic obstructive pulmonary disease	0.000305	0.00125	CcSEcCtD
Dolasetron—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—chronic obstructive pulmonary disease	0.000303	0.00824	CbGpPWpGaD
Dolasetron—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000302	0.00124	CcSEcCtD
Dolasetron—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000302	0.00124	CcSEcCtD
Dolasetron—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000296	0.00121	CcSEcCtD
Dolasetron—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000295	0.00121	CcSEcCtD
Dolasetron—CYP3A4—Estrogen metabolism—GSTM1—chronic obstructive pulmonary disease	0.00029	0.00791	CbGpPWpGaD
Dolasetron—Rash—Formoterol—chronic obstructive pulmonary disease	0.000288	0.00118	CcSEcCtD
Dolasetron—Rash—Arformoterol—chronic obstructive pulmonary disease	0.000288	0.00118	CcSEcCtD
Dolasetron—CYP2D6—Melatonin metabolism and effects—CYP1A1—chronic obstructive pulmonary disease	0.000288	0.00783	CbGpPWpGaD
Dolasetron—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.000287	0.00118	CcSEcCtD
Dolasetron—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.000287	0.00118	CcSEcCtD
Dolasetron—Headache—Formoterol—chronic obstructive pulmonary disease	0.000286	0.00117	CcSEcCtD
Dolasetron—Headache—Arformoterol—chronic obstructive pulmonary disease	0.000286	0.00117	CcSEcCtD
Dolasetron—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000285	0.00117	CcSEcCtD
Dolasetron—Rash—Montelukast—chronic obstructive pulmonary disease	0.000282	0.00115	CcSEcCtD
Dolasetron—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.000282	0.00115	CcSEcCtD
Dolasetron—Ill-defined disorder—Prednisolone—chronic obstructive pulmonary disease	0.000281	0.00115	CcSEcCtD
Dolasetron—Headache—Montelukast—chronic obstructive pulmonary disease	0.00028	0.00115	CcSEcCtD
Dolasetron—Acute coronary syndrome—Prednisone—chronic obstructive pulmonary disease	0.000278	0.00114	CcSEcCtD
Dolasetron—Angioedema—Prednisolone—chronic obstructive pulmonary disease	0.000277	0.00113	CcSEcCtD
Dolasetron—Myocardial infarction—Prednisone—chronic obstructive pulmonary disease	0.000276	0.00113	CcSEcCtD
Dolasetron—CYP3A4—Estrogen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000275	0.0075	CbGpPWpGaD
Dolasetron—Malaise—Prednisolone—chronic obstructive pulmonary disease	0.000273	0.00112	CcSEcCtD
Dolasetron—Vertigo—Prednisolone—chronic obstructive pulmonary disease	0.000272	0.00111	CcSEcCtD
Dolasetron—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000272	0.00111	CcSEcCtD
Dolasetron—Syncope—Prednisolone—chronic obstructive pulmonary disease	0.000272	0.00111	CcSEcCtD
Dolasetron—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000271	0.00111	CcSEcCtD
Dolasetron—Headache—Salbutamol—chronic obstructive pulmonary disease	0.00027	0.0011	CcSEcCtD
Dolasetron—Loss of consciousness—Prednisolone—chronic obstructive pulmonary disease	0.000266	0.00109	CcSEcCtD
Dolasetron—Convulsion—Prednisolone—chronic obstructive pulmonary disease	0.000262	0.00107	CcSEcCtD
Dolasetron—Hypertension—Prednisolone—chronic obstructive pulmonary disease	0.000261	0.00107	CcSEcCtD
Dolasetron—Bradycardia—Prednisone—chronic obstructive pulmonary disease	0.000257	0.00105	CcSEcCtD
Dolasetron—Discomfort—Prednisolone—chronic obstructive pulmonary disease	0.000255	0.00104	CcSEcCtD
Dolasetron—CYP2C9—Arachidonic acid metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000254	0.00691	CbGpPWpGaD
Dolasetron—CYP3A4—Xenobiotics—CYP1A1—chronic obstructive pulmonary disease	0.000253	0.00689	CbGpPWpGaD
Dolasetron—Anaphylactic shock—Prednisolone—chronic obstructive pulmonary disease	0.000247	0.00101	CcSEcCtD
Dolasetron—Oedema—Prednisolone—chronic obstructive pulmonary disease	0.000247	0.00101	CcSEcCtD
Dolasetron—CYP3A4—Tamoxifen metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000243	0.00663	CbGpPWpGaD
Dolasetron—Shock—Prednisolone—chronic obstructive pulmonary disease	0.000243	0.000995	CcSEcCtD
Dolasetron—Tachycardia—Prednisolone—chronic obstructive pulmonary disease	0.000241	0.000987	CcSEcCtD
Dolasetron—Hyperhidrosis—Prednisolone—chronic obstructive pulmonary disease	0.000239	0.000978	CcSEcCtD
Dolasetron—Flushing—Prednisone—chronic obstructive pulmonary disease	0.000235	0.00096	CcSEcCtD
Dolasetron—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP1A2—chronic obstructive pulmonary disease	0.000228	0.00621	CbGpPWpGaD
Dolasetron—CYP2D6—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000226	0.00616	CbGpPWpGaD
Dolasetron—Arrhythmia—Prednisone—chronic obstructive pulmonary disease	0.000226	0.000924	CcSEcCtD
Dolasetron—CYP2C9—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000224	0.00611	CbGpPWpGaD
Dolasetron—Paraesthesia—Prednisolone—chronic obstructive pulmonary disease	0.000222	0.000908	CcSEcCtD
Dolasetron—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.000221	0.00603	CbGpPWpGaD
Dolasetron—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.000219	0.00597	CbGpPWpGaD
Dolasetron—CYP2D6—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.000218	0.00595	CbGpPWpGaD
Dolasetron—CYP2C9—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.000216	0.0059	CbGpPWpGaD
Dolasetron—Pain—Prednisolone—chronic obstructive pulmonary disease	0.000211	0.000865	CcSEcCtD
Dolasetron—Ill-defined disorder—Prednisone—chronic obstructive pulmonary disease	0.000204	0.000836	CcSEcCtD
Dolasetron—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	0.000204	0.000834	CcSEcCtD
Dolasetron—Anaemia—Prednisone—chronic obstructive pulmonary disease	0.000203	0.000832	CcSEcCtD
Dolasetron—Agitation—Prednisone—chronic obstructive pulmonary disease	0.000202	0.000828	CcSEcCtD
Dolasetron—Angioedema—Prednisone—chronic obstructive pulmonary disease	0.000201	0.000823	CcSEcCtD
Dolasetron—Malaise—Prednisone—chronic obstructive pulmonary disease	0.000198	0.000812	CcSEcCtD
Dolasetron—Vertigo—Prednisone—chronic obstructive pulmonary disease	0.000198	0.000809	CcSEcCtD
Dolasetron—Syncope—Prednisone—chronic obstructive pulmonary disease	0.000197	0.000808	CcSEcCtD
Dolasetron—Urticaria—Prednisolone—chronic obstructive pulmonary disease	0.000196	0.000804	CcSEcCtD
Dolasetron—HTR3A—SIDS Susceptibility Pathways—CXCL8—chronic obstructive pulmonary disease	0.000194	0.00528	CbGpPWpGaD
Dolasetron—Loss of consciousness—Prednisone—chronic obstructive pulmonary disease	0.000193	0.000792	CcSEcCtD
Dolasetron—Convulsion—Prednisone—chronic obstructive pulmonary disease	0.000191	0.00078	CcSEcCtD
Dolasetron—Hypertension—Prednisone—chronic obstructive pulmonary disease	0.00019	0.000778	CcSEcCtD
Dolasetron—Myalgia—Prednisone—chronic obstructive pulmonary disease	0.000187	0.000767	CcSEcCtD
Dolasetron—Arthralgia—Prednisone—chronic obstructive pulmonary disease	0.000187	0.000767	CcSEcCtD
Dolasetron—Anxiety—Prednisone—chronic obstructive pulmonary disease	0.000187	0.000764	CcSEcCtD
Dolasetron—HTR3A—SIDS Susceptibility Pathways—IL1B—chronic obstructive pulmonary disease	0.000186	0.00507	CbGpPWpGaD
Dolasetron—Discomfort—Prednisone—chronic obstructive pulmonary disease	0.000185	0.000758	CcSEcCtD
Dolasetron—CYP2C9—Arachidonic acid metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000184	0.00502	CbGpPWpGaD
Dolasetron—Hypersensitivity—Prednisolone—chronic obstructive pulmonary disease	0.000182	0.000745	CcSEcCtD
Dolasetron—Oedema—Prednisone—chronic obstructive pulmonary disease	0.00018	0.000735	CcSEcCtD
Dolasetron—Anaphylactic shock—Prednisone—chronic obstructive pulmonary disease	0.00018	0.000735	CcSEcCtD
Dolasetron—CYP2D6—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000179	0.00489	CbGpPWpGaD
Dolasetron—CYP3A4—Tryptophan metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000179	0.00487	CbGpPWpGaD
Dolasetron—CYP2C9—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000178	0.00484	CbGpPWpGaD
Dolasetron—Shock—Prednisone—chronic obstructive pulmonary disease	0.000177	0.000723	CcSEcCtD
Dolasetron—Tachycardia—Prednisone—chronic obstructive pulmonary disease	0.000175	0.000717	CcSEcCtD
Dolasetron—Hyperhidrosis—Prednisone—chronic obstructive pulmonary disease	0.000174	0.000711	CcSEcCtD
Dolasetron—Anorexia—Prednisone—chronic obstructive pulmonary disease	0.000171	0.000701	CcSEcCtD
Dolasetron—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	0.000164	0.00067	CcSEcCtD
Dolasetron—Dizziness—Prednisolone—chronic obstructive pulmonary disease	0.000163	0.000669	CcSEcCtD
Dolasetron—Paraesthesia—Prednisone—chronic obstructive pulmonary disease	0.000161	0.00066	CcSEcCtD
Dolasetron—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	0.000161	0.00438	CbGpPWpGaD
Dolasetron—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	0.000159	0.00434	CbGpPWpGaD
Dolasetron—CYP2D6—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	0.000159	0.00432	CbGpPWpGaD
Dolasetron—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	0.000158	0.000647	CcSEcCtD
Dolasetron—HTR3A—SIDS Susceptibility Pathways—VEGFA—chronic obstructive pulmonary disease	0.000157	0.00429	CbGpPWpGaD
Dolasetron—CYP2C9—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	0.000157	0.00428	CbGpPWpGaD
Dolasetron—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	0.000156	0.000639	CcSEcCtD
Dolasetron—Rash—Prednisolone—chronic obstructive pulmonary disease	0.000156	0.000638	CcSEcCtD
Dolasetron—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	0.000156	0.000637	CcSEcCtD
Dolasetron—Fatigue—Prednisone—chronic obstructive pulmonary disease	0.000155	0.000634	CcSEcCtD
Dolasetron—Headache—Prednisolone—chronic obstructive pulmonary disease	0.000155	0.000634	CcSEcCtD
Dolasetron—Constipation—Prednisone—chronic obstructive pulmonary disease	0.000154	0.000629	CcSEcCtD
Dolasetron—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	0.000148	0.000606	CcSEcCtD
Dolasetron—CYP3A4—Metapathway biotransformation—EPHX1—chronic obstructive pulmonary disease	0.000148	0.00403	CbGpPWpGaD
Dolasetron—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	0.000147	0.000601	CcSEcCtD
Dolasetron—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A2—chronic obstructive pulmonary disease	0.000145	0.00394	CbGpPWpGaD
Dolasetron—CYP3A4—Oxidation by Cytochrome P450—CYP1A2—chronic obstructive pulmonary disease	0.000143	0.00389	CbGpPWpGaD
Dolasetron—Urticaria—Prednisone—chronic obstructive pulmonary disease	0.000143	0.000584	CcSEcCtD
Dolasetron—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	0.000142	0.000581	CcSEcCtD
Dolasetron—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	0.000142	0.000581	CcSEcCtD
Dolasetron—HTR3A—SIDS Susceptibility Pathways—TNF—chronic obstructive pulmonary disease	0.000135	0.00368	CbGpPWpGaD
Dolasetron—Hypersensitivity—Prednisone—chronic obstructive pulmonary disease	0.000132	0.000542	CcSEcCtD
Dolasetron—CYP2D6—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	0.00013	0.00355	CbGpPWpGaD
Dolasetron—CYP3A4—Tryptophan metabolism—CYP1A1—chronic obstructive pulmonary disease	0.00013	0.00354	CbGpPWpGaD
Dolasetron—CYP2C9—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	0.000129	0.00352	CbGpPWpGaD
Dolasetron—Asthenia—Prednisone—chronic obstructive pulmonary disease	0.000129	0.000527	CcSEcCtD
Dolasetron—HTR3A—Transmembrane transport of small molecules—HMOX1—chronic obstructive pulmonary disease	0.000128	0.0035	CbGpPWpGaD
Dolasetron—Pruritus—Prednisone—chronic obstructive pulmonary disease	0.000127	0.00052	CcSEcCtD
Dolasetron—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	0.000123	0.000503	CcSEcCtD
Dolasetron—Dizziness—Prednisone—chronic obstructive pulmonary disease	0.000119	0.000486	CcSEcCtD
Dolasetron—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A2—chronic obstructive pulmonary disease	0.000117	0.00319	CbGpPWpGaD
Dolasetron—CYP2D6—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	0.000115	0.00312	CbGpPWpGaD
Dolasetron—CYP2C9—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	0.000114	0.0031	CbGpPWpGaD
Dolasetron—CYP2D6—Biological oxidations—GCLC—chronic obstructive pulmonary disease	0.000113	0.00309	CbGpPWpGaD
Dolasetron—Rash—Prednisone—chronic obstructive pulmonary disease	0.000113	0.000463	CcSEcCtD
Dolasetron—Dermatitis—Prednisone—chronic obstructive pulmonary disease	0.000113	0.000463	CcSEcCtD
Dolasetron—Headache—Prednisone—chronic obstructive pulmonary disease	0.000112	0.00046	CcSEcCtD
Dolasetron—CYP2C9—Biological oxidations—GCLC—chronic obstructive pulmonary disease	0.000112	0.00306	CbGpPWpGaD
Dolasetron—HTR3A—SIDS Susceptibility Pathways—IL6—chronic obstructive pulmonary disease	0.000109	0.00297	CbGpPWpGaD
Dolasetron—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—chronic obstructive pulmonary disease	0.000105	0.00286	CbGpPWpGaD
Dolasetron—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—chronic obstructive pulmonary disease	0.000104	0.00283	CbGpPWpGaD
Dolasetron—CYP2D6—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	9.53e-05	0.0026	CbGpPWpGaD
Dolasetron—CYP2C9—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	9.44e-05	0.00257	CbGpPWpGaD
Dolasetron—CYP2D6—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	9.39e-05	0.00256	CbGpPWpGaD
Dolasetron—CYP2C9—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	9.31e-05	0.00254	CbGpPWpGaD
Dolasetron—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—chronic obstructive pulmonary disease	8.52e-05	0.00232	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—GC—chronic obstructive pulmonary disease	7.99e-05	0.00218	CbGpPWpGaD
Dolasetron—CYP2D6—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	7.94e-05	0.00216	CbGpPWpGaD
Dolasetron—CYP2C9—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	7.88e-05	0.00215	CbGpPWpGaD
Dolasetron—CYP2D6—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	7.84e-05	0.00213	CbGpPWpGaD
Dolasetron—CYP2C9—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	7.77e-05	0.00212	CbGpPWpGaD
Dolasetron—HTR3A—Transmembrane transport of small molecules—ALB—chronic obstructive pulmonary disease	7.71e-05	0.0021	CbGpPWpGaD
Dolasetron—CYP3A4—Biological oxidations—GSTT1—chronic obstructive pulmonary disease	7.49e-05	0.00204	CbGpPWpGaD
Dolasetron—CYP3A4—Biological oxidations—GCLC—chronic obstructive pulmonary disease	7.41e-05	0.00202	CbGpPWpGaD
Dolasetron—CYP2D6—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	7.3e-05	0.00199	CbGpPWpGaD
Dolasetron—CYP2C9—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	7.24e-05	0.00197	CbGpPWpGaD
Dolasetron—CYP2D6—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	7.2e-05	0.00196	CbGpPWpGaD
Dolasetron—CYP2C9—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	7.14e-05	0.00194	CbGpPWpGaD
Dolasetron—CYP2D6—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	6.92e-05	0.00189	CbGpPWpGaD
Dolasetron—CYP2C9—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	6.86e-05	0.00187	CbGpPWpGaD
Dolasetron—CYP2D6—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	6.83e-05	0.00186	CbGpPWpGaD
Dolasetron—CYP2C9—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	6.77e-05	0.00184	CbGpPWpGaD
Dolasetron—CYP3A4—Biological oxidations—CYP1A2—chronic obstructive pulmonary disease	6.23e-05	0.0017	CbGpPWpGaD
Dolasetron—CYP3A4—Metapathway biotransformation—CYP1A2—chronic obstructive pulmonary disease	6.14e-05	0.00167	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—APIP—chronic obstructive pulmonary disease	5.57e-05	0.00152	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—APIP—chronic obstructive pulmonary disease	5.52e-05	0.0015	CbGpPWpGaD
Dolasetron—CYP3A4—Biological oxidations—GSTP1—chronic obstructive pulmonary disease	5.19e-05	0.00142	CbGpPWpGaD
Dolasetron—CYP3A4—Metapathway biotransformation—GSTP1—chronic obstructive pulmonary disease	5.12e-05	0.0014	CbGpPWpGaD
Dolasetron—CYP3A4—Biological oxidations—GSTM1—chronic obstructive pulmonary disease	4.77e-05	0.0013	CbGpPWpGaD
Dolasetron—CYP3A4—Metapathway biotransformation—GSTM1—chronic obstructive pulmonary disease	4.71e-05	0.00128	CbGpPWpGaD
Dolasetron—CYP3A4—Biological oxidations—CYP1A1—chronic obstructive pulmonary disease	4.52e-05	0.00123	CbGpPWpGaD
Dolasetron—CYP3A4—Metapathway biotransformation—CYP1A1—chronic obstructive pulmonary disease	4.46e-05	0.00122	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—CTGF—chronic obstructive pulmonary disease	3.94e-05	0.00107	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	3.69e-05	0.001	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	3.66e-05	0.000996	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—APIP—chronic obstructive pulmonary disease	3.64e-05	0.000992	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A2—chronic obstructive pulmonary disease	3.63e-05	0.000988	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—GC—chronic obstructive pulmonary disease	3.59e-05	0.000977	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—GC—chronic obstructive pulmonary disease	3.56e-05	0.000969	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	3.34e-05	0.000909	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	3.31e-05	0.000901	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—chronic obstructive pulmonary disease	2.63e-05	0.000718	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—RAPGEF3—chronic obstructive pulmonary disease	2.41e-05	0.000657	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—GC—chronic obstructive pulmonary disease	2.35e-05	0.000639	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—ALDH7A1—chronic obstructive pulmonary disease	2.18e-05	0.000594	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.96e-05	0.000534	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.94e-05	0.000529	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—GCLC—chronic obstructive pulmonary disease	1.94e-05	0.000528	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—GCLC—chronic obstructive pulmonary disease	1.92e-05	0.000523	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism of lipids and lipoproteins—ALB—chronic obstructive pulmonary disease	1.79e-05	0.000488	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—CTGF—chronic obstructive pulmonary disease	1.77e-05	0.000482	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—CTGF—chronic obstructive pulmonary disease	1.75e-05	0.000478	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.63e-05	0.000444	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.61e-05	0.00044	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.36e-05	0.00037	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—GSTP1—chronic obstructive pulmonary disease	1.35e-05	0.000367	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.34e-05	0.000365	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—HMOX1—chronic obstructive pulmonary disease	1.33e-05	0.000362	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—GSTT1—chronic obstructive pulmonary disease	1.28e-05	0.000349	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—GCLC—chronic obstructive pulmonary disease	1.27e-05	0.000345	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.25e-05	0.00034	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—GSTM1—chronic obstructive pulmonary disease	1.24e-05	0.000337	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.18e-05	0.000322	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—CYP1A1—chronic obstructive pulmonary disease	1.17e-05	0.00032	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—CTGF—chronic obstructive pulmonary disease	1.16e-05	0.000315	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—CYP1A2—chronic obstructive pulmonary disease	1.07e-05	0.00029	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—GSTP1—chronic obstructive pulmonary disease	8.88e-06	0.000242	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—HMOX1—chronic obstructive pulmonary disease	8.76e-06	0.000239	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—GSTM1—chronic obstructive pulmonary disease	8.16e-06	0.000222	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—ALB—chronic obstructive pulmonary disease	8.05e-06	0.000219	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—ALB—chronic obstructive pulmonary disease	7.98e-06	0.000217	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—CYP1A1—chronic obstructive pulmonary disease	7.74e-06	0.000211	CbGpPWpGaD
Dolasetron—CYP2D6—Metabolism—NOS3—chronic obstructive pulmonary disease	7.7e-06	0.00021	CbGpPWpGaD
Dolasetron—CYP2C9—Metabolism—NOS3—chronic obstructive pulmonary disease	7.63e-06	0.000208	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—ALB—chronic obstructive pulmonary disease	5.26e-06	0.000143	CbGpPWpGaD
Dolasetron—CYP3A4—Metabolism—NOS3—chronic obstructive pulmonary disease	5.03e-06	0.000137	CbGpPWpGaD
